The Muscular Dystrophy Association (MDA) called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), ...
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, g...
GE HealthCare announced the submission of a 510(k) to the U.S. FDA seeking clearance for Photonova™ Spectra, its new photon-counting computed ...
MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, announced two major...
-Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the U....
ADVANCE®AI, a leading innovator in pharmaceutical-specific AI solutions, is excited to announce our acceptance into the Microsoft for Startups Pegasu...
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blin...
MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills ...
Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia Represents a major step...
Test will serve as a companion diagnostic for Bayer’s HYRNUO™ (sevabertinib) to identify patients with NSCLC eligible for HER2-targeted...
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived p...
SciSparc Ltd. announced that NeuroThera Labs Inc. , a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous sy...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030 Enables manufacturing...
© 2025 Biopharma Boardroom. All Rights Reserved.
